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1. Introduction 
Chronic renal failure (CRF) is associated with life-threatening accumulation of metabolic 
products due to the inability of their elimination. On hemodialysis, toxic substances are 
eliminated from the site of their high concentration (blood) via semipermeable membrane to 
a lower concentration medium (dialysis fluid) by the principle of diffusion. Hemodialysis 
has been widely used since the end of the 1960s. Although hemodialysis significantly 
prolongs life expectancy in CRF patients, hemodialyzers cannot compensate for all kidney 
functions. Hemodialyzer function has been greatly upgraded by technical innovations, 
however, many kidney functions in the regulation of homeostasis such as hormone 
production, e.g., vitamin D active metabolite (calcitriol) and erythropoietin, and many other 
functions remain unfeasible. Kidneys are involved in mineral metabolism and are target 
organs for the action of parathormone. In CRF patients, bone metabolism  impairment 
occurs at creatinine clearance of 50-60 mL/min. Therefore, prolonged duration of 
hemodialysis is associated with development of numerous complications, in particular those 
involving the osteoarticular system. These complications are due to osteodystrophy and 
dialysis related amyloidosis (DRA). Tenosinovitis, in particular involving finger and hand 
flexors, snapping fingers and joint contractures are frequently present, however, tendon 
rupture may also occur. Muscle atrophy leads to the loss of strength, inability to perform 
fine finger movements, with a reduced function and range of movements and joint 
contractures. The hands assume a typical shape of so-called amyloid hand, while fingers 
look like "guitar players" (Farrell & Bastani, 1997; Fitzpatrick et al., 1996). Pain, swelling, 
degenerative joint changes and effusions are bilateral and symmetric, and may vary from 
very mild through severe where movements are painful and limited (Kelly et al., 2007; 
Zhang et al., 2002).  Shoulders, hips and knees are mostly involved, however, all other joints 
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may also be affected (Yamamoto et al., 2008). Soft tissue and joint lesions lead to dysfunction 
of the musculoskeletal system. Subchondral cysts are seen on the bones and erosions on the 
joints; pathologic bone fractures may occur in advanced stages of amyloidosis. The number 
and size of the cysts increase with the length of dialysis. Amyloid bone cysts may frequently 
be misinterpreted as tumors. On x-ray study, amyloid cysts can be differentiated from 
"brown" tumors. Whereas the former are found in distal part of the bone, frequently 
bilateral, multiple, well delineated and with sclerotic edges, located subchondrally or in the 
area of ligament junction, "brown" tumors are found in the are of long bone diaphysis. β2-
microglobulin is a polypeptide, molecular weight of 11800 daltons, found on the surface of 
most nucleated cells. Lymphocytes and T cells play a crucial role in the formation of β2-
microglobulin. In normal individuals, β2-microglobulin is found in tissue fluids, synovia, 
serum and urine, filtered via glomerular filtration, resorbed and degraded in proximal 
tubules. Reduced function of proximal tubules results in elevated β2-microglobulin level in 
urine. Elevated serum β2-microglobulin levels may be due to its enhanced synthesis, as in 
some inflammatory diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, 
Sjögren's syndrome, Crohn's disease, cytomegalovirus infection, infectious mononucleosis, 
hepatitis C, HIV infection, chronic osteomyelitis), or malignant and lymphoproliferative 
diseases (multiple myeloma, β-cell lymphoma, chronic lymphocytic leukemia), or because of 
its decreased secretion due to reduced glomerular filtration in CRF patients. A number of 
factors are responsible for elevated β2-microglobulin level in the blood of hemodialysis 
patients. About 100-200 g β2-microglobulin or 2-4 mg/kg body weight are synthesized per 
day, its reference plasma values ranging from 0.73 to 3.81 mg/L (Al-Taee et al., 2003; Farrell 
& Bastani, 1997;). In CRF patients, there is no β2-microglobulin elimination, thus its 
concentration being 15 to 60 fold normal values (Motomiya et al., 2001; Ohashi, 2001).  
In human body, β2-microglobulin is found in extracellular space, circulates as a free 
monomer and does not bind to plasma proteins (Connors et al., 1985). By polymerization, 
β2-microglobulin is transformed from soluble to insoluble form and accumulated in the 
form of amyloid deposits in various tissues causing structural and functional organ 
lesions. The complications that develop due to amyloid accumulation involve visceral 
organs and osteoarticular system in particular. The visceral form of amyloidosis involves 
numerous organs, e.g., heart, lungs, gastrointestinal system and urogenital system; 
subcutaneous amyloid deposits are quite common, in particular those involving gluteal 
region, and may also be found intradermally around hair follicles, sebaceous glands and 
blood vessels (Jimenez et al., 1998). In amyloidosis involving osteoarticular system, 
amyloid is accumulated between cells (in the interstitium) but rarely in blood vessels, 
whereas in case of visceral complications in CRF patients, subendothelial amyloid 
accumulation is seen with deposits in vascular walls to produce intraluminal protrusions 
in blood vessels. In the second half of the 1970s, carpal tunnel syndrome was observed to 
occur in hemodialysis patients due to accumulation of a new amyloid type (Kenzora, 
1978; Warren & Otieno, 1975). In 1985, Geyo et al. demonstrated β2-microglobulin to be 
responsible for the development of a new type of amyloidosis in CRF patients (Denesh & 
Ho, 1998; Geyo et al., 1985; Tsvetkova et al., 2007). According to the World Health 
Organization 1993 nomenclature, amyloidosis in CRF patients is termed Aβ2m-
amyloidosis. It is the most common complication in CRF patients. In the literature, a 
number of synonyms have been used for this type of amyloidosis, i.e. AB amyloidosis, 
dialysis amyloidosis, and dialysis related amyloidosis (DRA). As clinical manifestations of 
this complication occur in the advanced stage of the disease, it is necessary to detect it in 
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its preclinical stage. Therefore, the lesions should be detected and followed-up before the 
clinical signs of the disease occur, and properly controlled during treatment. There are 
several diagnostic procedures used to follow-up the lesions involving osteoarticular 
system, e.g., x-ray, computed tomography (CT), magnetic resonance imaging (MRI), 
scintigraphy, biopsy, and ultrasonography (US). Changes of the osseous and articular 
structures are analyzed by use of x-ray studies. Radiological signs of arthropathy are 
present in patients undergoing hemodialysis for more than 5 years (Tsvetkova et al., 
2007). X-ray is a presumptive method, i.e. bone lesions can be identified even before pain 
occurs. Changes are seen as typically distributed subchondral cystic bone lesions, usually 
of thin and sclerotic edges, joint erosions, and possibly pathologic fractures. After 10-year 
hemodialysis, 50%-60% of patients show bone cysts (Fitzpatrick et al., 1996). X-ray 
changes are not seen in early stages of the disease. Distribution and extension of amyloid 
pseudotumors and pseudocysts of bones and joints, around joints, small areas of 
osteolysis or cortical bone erosion are visualized by CT, however, this study is associated 
with exposure to higher irradiation doses (Kiss et al., 2005). MRI offers useful data on 
bone, joint and soft tissue changes and particular organ involvement (Fukuda & 
Yamamoto, 2001; Kiss et al., 2005), however, MRI is a more expensive, less available and 
more time consuming method, and therefore less commonly employed in clinical routine. 
The usual noninvasive diagnostic studies include US, classic x-ray and MRI. However, 
these are nonspecific and low sensitivity studies. Scintigraphy is a specific noninvasive 
diagnostic method used to identify amyloidosis distribution and extension all over the 
body (Floege et al., 2001; Hawkins et al., 1990; Ketteler et al., 2001; Linke et al., 2000). 
Three scintigraphy methods are most widely employed: standard bone scintigraphy by 
use of Tc-diphosphonates; scintigraphy with iodine 123I labeled serum amyloid P 
component (SAP); and scintigraphy by use of specific protein precursors in Aβ2M 
amyloid (131I-β2m). Biopsy is an invasive diagnostic method providing an insight into the 
local area lesions; however, it may be associated with periprocedural complications. Joint 
effusion puncture, rectal biopsy, abdominal adipose tissue biopsy (aspiration) and 
salivary gland biopsy are most commonly performed. Histologic changes of soft tissue 
develop far before clinical signs of the disease. Clinical signs of hemodialysis related 
amyloidosis occur in advanced stages of the disease. As clinical symptoms are 
nonspecific, they may easily be misinterpreted as other joint diseases. Patients undergoing 
hemodialysis for less than 5 years rarely show clinical signs of amyloidosis (Al-Taee et al., 
2003). Carpal tunnel syndrome frequently occurs as the first clinical sign of amyloidosis 
(Ikegava et al., 1995; Shin et al., 2008). The number and severity of clinical symptoms are 
known to increase with the length of hemodialysis. After 15-year hemodialysis, clinical 
symptoms of hemodialysis related amyloidosis are present in 100% of patients (Al-Taee et 
al., 2003). Therefore, it is of utmost importance to follow-up the course of disease in its 
preclinical stage. There are direct and indirect diagnostic procedures used to demonstrate 
amyloidosis. An ideal diagnostic study should be noninvasive, repeatable, highly specific, 
inexpensive and widely available. Tissue biopsy is considered as the 'gold standard' to 
demonstrate amyloidosis, however, other diagnostic methods are also employed to reach 
the diagnosis. US has been widely accepted in the diagnosis of pathology, of the 
osteoarticular system soft tissues in particular. New US high-resolution devices with 
many technological innovations (e.g., offering the possibility of changing the frequency, 
focus, 3D image, using probes of various shape and size, movement analysis, i.e. real-time 
study, etc.) can measure morphological changes with precision of tenths of millimeter. 
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Hemodialysis patients mostly show lesions of soft tissues, in particular tendons and 
synovial sheaths, with frequent tenosinovitis and joint effusion. On US, muscle lesions can 
be visualized, thickness of tendons, ligaments and joint sheaths measured, lesions of para-
articular structures observed, and extent of joint effusion followed-up; tissue 
vascularization can be followed-up by Doppler US. Although not highly specific, US is a 
presumptive, widely available, noninvasive, repeatable and inexpensive study free from 
ionizing radiation that can be used to follow-up the course of the disease, therapeutic 
effects and possible complications involving the osteoarticular system in CRF patients. US 
can be used as a control tool on therapy administration or puncture of joints, bursae, 
cysts, ganglia, or on tissue biopsy. The aim of the present study was to assess the impact 
of hemodialysis duration, patient age and β2-microglobulin concentration at the onset of 
hemodialysis on morphological changes in the hip region. 
2. Patients and methods 
Bilateral hip US using a 7-cm linear probe of 7.5 MHz was performed in 106 hemodialysis 
patients aged >18 to measure articular sheath thickness and articular effusion in both hips. 
During the procedure, the patient was in supine position, with the leg in neutral position. 
We used anterior longitudinal approach where the probe is parallel to femoral neck axis. 
Thickness of the hip joint sheath measured in the concave segment of the femur was 
determined as distance from the joint sheath inner to outer edge. Synovial effusion in the 
hip region was expressed as distance between anterior cortex of the femoral neck concave 
segment and inner edge of the hip joint sheath. A total of 424 US measurements were 
performed in the study group and 204 bilateral measurements in the control group. Control 
group consisted of 51 healthy subjects that underwent the same measurements of hip joint 
sheath thickness and articular effusion. Study patients were divided into three groups 
according to the length of hemodialysis (<36, 36-72 and >72 months) and age (18-50, 51-65 
and >65 years). In study patients, serum β2-microglobulin concentration was determined at 
the onset of hemodialysis, and in control subjects before US examination. All laboratory 
tests were performed at Laboratory of Biochemistry, Požega General Hospital, in Požega, 
Croatia. Beta2-microglobulin concentration was determined by use of the AxSYM β2-
microglobulin microparticle enzyme immunoassay (MEIA; Abbott GmbH, Wiesbaden, 
Germany). Blood samples were obtained from cubital vein by use of Vacutainer system. 
Blood sample was centrifuged for 10 min at 3500 rpm within 5 hours of venepuncture. 
Subjects with a history of previous injury or operative procedure on the study joints, 
inflammatory (chronic osteomyelitis, tuberculosis, HIV infection, hepatitis C), malignant or 
rheumatic diseases, systemic lupus erythematosus, sarcoidosis, Sjögren's syndrome, Crohn's 
disease, or lymphoproliferative diseases (multiple myeloma, β-cell lymphoma, chronic 
lymphocytic leukemia) were excluded. All study patients were undergoing hemodialysis 
with low-flux hemodialyzers. All examinations were performed by the author himself in 
order to prevent inter-examiner finding variability. All study subjects were informed on the 
study protocol, objectives and methods used, expected benefits, possible risks, etc. Inclusion 
in the study was voluntary and all subjects signed the informed consent form. Study 
protocol was approved by the Ethics Committees of the Požega General County Hospital, 
Dr. Josip Benčević General Hospital from Slavonski Brod, and School of Medicine, 
University of Zagreb from Zagreb, Croatia. 
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3. Statistical methods 
Kruskal-Wallis test was used to test significance of differences between different age groups. 
In addition, differences between pairs of groups were tested with Mann Whitney U-tests. 
Spearman's rank correlation coefficient was used to test correlation between age and 
concentration of β2M. Data were presented as mean, minimum and maximum in tables. The 
chosen level of statistical significance was p<0.05. 
4. Results 
Thickness of the hip joint sheath and articular effusion were measured bilaterally in 106 
hemodialysis patients and the measured values were compared with those recorded in 51 
control subjects. Measurement results were compared according to the length of 
hemodialysis, body side, age, sex, β2-microglobulin concentration, and measured thickness 
of the hip joint sheath and articular effusion in control subjects. The mean age of patients 
undergoing hemodialysis at the time of examination was 64.0 (range 28.2-87.4) years. There 
were 55 male patients, mean age 60.5 (28.2-87.4) years and 51 female patients, mean age 67.9 
(30.7-82.0) years. The mean length of hemodialysis in 18-50, 51-65 and >65 age groups was 
16, 53 and 123 months, respectively, mean 56.3 months. In control group consisting of 51 
healthy volunteers, the mean age was 62.6 (40.0-86.4) years. There were 25 male subjects, 
mean age 61.6 (40.0-86.4) years and 26 female subjects, mean age 63.6 (40.5-81.0) years. There 
was no statistically significant difference in age between hemodialysis patients and controls 
(P0.05). The US measured thickness of hip joint sheath and articular effusion in control 
group according to age groups is shown in Tables 1 and 2, respectively. 
 
 
Age (yrs) 
 Hip joint sheath thickness (mm) 
n M Min Max 
18-50 7 5.36 3.90 7.50 
51-65 21 5.33 3.90 7.30 
>65 23 4.69 3.10 7.50 
Total 51 5.04 3.10 7.50 
n = number of subjects; M = mean (mm) 
Table 1. Number of subjects, age, and hip joint sheath thickness in control group. 
 
 
Age (yrs) 
 Articular effusion thickness (mm) 
n M Min Max 
18-50 7 4.11 1.10 6.40 
51-65 21 4.85 0.80 7.10 
>65 23 4.44 2.10 7.00 
Total 51 4.56 0.80 7.10 
n = number of subjects; M = mean (mm) 
Table 2. Number of subjects, age, and articular effusion thickness in control group. 
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The US measured thickness of the hip joint sheath and articular effusion using anterior 
longitudinal approach with the probe parallel to the femoral neck axis is presented in Figure 
1.  
 
 
Fig. 1. US image of the hip joint sheath and intra-articular effusion. 
The US measured thickness of hip joint sheath according to the length of hemodialysis and 
patient age is presented in Table 3 A and B. 
 
 
 
Age 
(yrs) 
Length of hemodialysis 
<36 months 36-72 months >72 months 
n M Min Max n M Min Max n M Min Max 
18-50 8 5.30 3.90 6.50 5 6.32 5.10 7.40 3 7.93 6.70 9.00 
51-65 10 5.45 4.00 6.90 9 6.44 5.00 8.70 7 6.86 4.20 8.50 
>65 24 5.53 3.10 7.10 23 6.70 5.10 8.00 17 7.20 3.30 10.3 
Total 42 5.47 3.10 7.10 37 6.59 5.00 8.70 27 7.19 3.30 10.3 
n = number of patients; M = mean (mm) 
Table 3A. Number of patients and hip joint sheath thickness according to patient age and 
length of hemodialysis.  
Femur 
neck 
Hip joint 
sheath 
Synovial 
effusion 
Right Left 
Femur 
head 
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Age (yrs) 
Length of hemodialysis 
Total 
n M Min Max 
18-50 16 6.11 3.90 9.00 
51-65 26 6.17 4.00 8.70 
>65 64 6.39 3.10 10.3 
Total 106 6.30 3.10 10.3 
n = number of patietns; M = mean (mm) 
Table 3B. Number of patients and hip joint sheath thickness according to patient age and 
length of hemodialysis (total). 
Simple analysis of variance for independent samples with the length of hemodialysis 
(categorized into three groups) as independent variable, and hip joint sheath thickness and 
articular effusion as dependent variables was performed to assess the impact of 
hemodialysis duration on thickness of the hip joint sheath and articular effusion. A 
statistically significant difference was found in thickness of the hip joint sheath and articular 
effusion between groups of patients with different length of hemodialysis, as indicated by 
the results of simple analysis of variance: joint sheath thickness F=21.319; df=2/103; P<0.01 
on the right; and F=21.011; df=2/103; P<0.01 on the left; and articular effusion: F=3.227; 
df=2/103; P<0.05 on the right; and F=4.479; df=2/103; P<0.05 on the left. Subsequent Tukey 
HSD test yielded a statistically significant difference in the hip joint sheath thickness among 
the three groups of hemodialysis patients. A statistically significant difference was found in 
the hip joint sheath thickness between the groups of patients with the length of 
hemodialysis <36 months and 36-72 months, <36 months and >72 months, 36-72 months and 
>72 months (P<0.01 all). Thickness of the hip joint sheath increased with the duration of 
hemodialysis. These differences were statistically significant on both the left and right side 
of the body. Subsequent Tukey HSD test yielded a statistically significant difference in hip 
joint intra-articular effusion between the groups of patients on hemodialysis for <36 months 
and >72 months (P<0.05). The magnitude of hip joint intra-articular effusion was 
significantly lower in the group of patients on hemodialysis for <36 months. Accordingly, 
the length of hemodialysis influenced the magnitude of articular effusion. Thickness of the 
hip joint sheath and articular effusion increased with the length of hemodialysis. Differences 
were statistically significant bilaterally.  Comparison of the hip joint sheath thickness and 
articular effusion according to body sides yielded no statistically significant difference, as 
indicated by the nonsignificant t-ratio (joint sheath thickness: t=1.739; df=105, and articular 
effusion: t=0.633; df=105; P>0.05 both). Hip joint sheath thickness and articular effusion 
were compared according to patient sex by use of t-test for independent samples. A 
statistically significant sex difference was found in both hip joint sheath thickness and 
articular effusion bilaterally, as follows: hip joint sheath thickness t=2.479; df=104; P<0.05 
(right) and t=3.138; df=104; P<0.01 (left), and articular effusion t=2.075; df=104 (right) and 
t=2.332; df=104 (left); P<0.05 both. The measured thickness of the hip joint sheath and 
articular effusion were greater bilaterally in male than in female patients.  Simple analysis of 
variance for independent samples with age (categorized into three groups) as independent 
variable, and hip joint sheath thickness and articular effusion as dependent variables was 
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performed to assess the impact of age on hip joint sheath thickness and articular effusion. 
The analysis of variance yielded the following results: F=0.437; df=2/103 (right) and 
F=0.496; df=2/103 (left); P>0.05 both. There was no statistically significant difference in the 
hip joint sheath thickness among the three age groups on either side of the body. The same 
analysis of variance was also performed with various age groups and magnitude of articular 
effusion in the hip region, with the following results: F=3.252; df=2/103 (right) and F=3.023; 
df=2/103 (left); P>0.05 both. There was no statistically significant difference in the 
magnitude of articular effusion among the three age groups on either side of the body. 
Accordingly, patient age was not found to influence thickness of the hip joint sheath and 
intra-articular effusion. 
Beta2-microglobulin concentration was determined before hemodialysis in the three patient 
age groups having undergone hemodialysis for a variable period of time. These results are 
shown in Table 4 A and B. 
 
 
Age (yrs) 
Length of hemodialysis 
<36 months 36-72 months 
n M Min Max n M Min Max 
18-50 8 31.020 19.874 42.662 5 34.331 25.580 43.688 
51-65 10 28.586 10.115 50.864 9 29.241 11.032 41.376 
>65 24 26.793 10.116 42.129 23 30.704 15.552 44.824 
Total 42 28.025 10.115 50.864 37 30.838 11.032 44.824 
n = number of patients; M = mean β2-microglobulin concentration (mg/L) 
Table 4A. β2-microglobulin concentration in three patient age groups undergoing 
hemodialysis for <36 months and 36-72 months. 
 
 
Age (yrs) 
Length of hemodialysis 
>72 months Total 
n M Min Max n M Min Max 
18-50 3 44.340 35.915 53.147 16 34.552 19.874 53.147 
51-65 7 32.122 16.188 51.791 26 29.764 10.115 51.797 
>65 17 32.069 10.328 47.997 64 29.600 10.116 47.997 
Total 27 33.446 10.328 53.147 106 30.388 10.115 53.147 
n = number of patients; M = mean β2-microglobulin concentration (mg/L) 
Table 4B. β2-microglobulin concentration in three patient age groups undergoing 
hemodialysis for <72 months and total. 
Simple analysis of variance for independent samples with the length of hemodialysis 
(categorized into three groups) as independent variable, and pre-hemodialysis β2-
microglobulin concentration as dependent variable performed to assess the possible impact 
of the length of hemodialysis on pre-hemodialysis β2-microglobulin concentration produced 
the following results: F=3.262; df=2/103; P<0.05. Subsequent Tukey HSD test yielded a 
statistically significant difference in pre-hemodialysis β2-microglobulin concentration 
between patient groups with hemodialysis duration <36 and >72 months (P<0.05). Pre-
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hemodialysis β2-microglobulin concentration was higher in the patient group with >72-
month hemodialysis duration as compared with those with <36 month hemodialysis 
duration. Accordingly, longer hemodialysis duration was associated with higher β2-
microglobulin concentration. In addition, β2-microglobulin concentration was correlated 
with patient age to assess the possible effect of age on pre-hemodialysis β2-microglobulin 
concentration. Simple analysis of variance for independent samples with age (categorized 
into three groups) as independent variable and pre-hemodialysis β2-microglobulin 
concentration as dependent variable was done to check for statistically significant 
differences in β2-microglobulin concentration among patients from different age groups. 
The analysis of variance yielded the following results: F=2.114; df=2/103; P0.05. 
Accordingly, there was no statistically significant difference in pre-hemodialysis β2-
microglobulin concentration among the three age groups; thus, patient age had no impact 
on pre-hemodialysis β2-microglobulin concentration in serum. The hip joint sheath 
thickness relative to β2-microglobulin concentration was compared between groups of 
patients with different length of hemodialysis. A statistically significant correlation between 
β2-microglobulin concentration and hip joint sheath thickness was recorded in the group of 
patients on hemodialysis for up to 36 months on the right side (r=0.310; P<0.05). In this 
group of patients, the higher the β2-microglobulin concentration, the higher was the hip 
joint sheath thickness. In the other two groups of patients on hemodialysis for 36-72 months 
and >72 months there was no statistically significant correlation between β2-microglobulin 
concentration and hip joint sheath thickness on either side of the body. The magnitude of 
hip joint intra-articular effusion and β2-microglobulin concentration were correlated in the 
groups of patients with different length of hemodialysis, yielding no statistically significant 
correlation between the two parameters in any of the patient groups. Pre-hemodialysis β2-
microglobulin concentration had no effect on the magnitude of hip joint intra-articular 
effusion in any of the patient groups with different length of hemodialysis. The mean β2-
microglobulin concentration was 1.662 mg/L in control group and 30.388 mg/L in overall 
patient group (28.025, 30.838 and 33.446 mg/L in patient groups on hemodialysis for <36, 
36-72 and >72 months, respectively), i.e. 18.3-fold concentration in control group (P<0.05). 
The mean β2-microglobulin concentrations recorded in three control age groups are shown 
in Table 5. 
 
 
 
 
Age (yrs) 
Total 
n M Min Max 
18-50 7 1.133 0.942 1.537 
51-65 21 1.541 0.963 2.617 
>65 23 1.934 1.130 2.836 
Total 51 1.662 0.942 2.836 
n = number of subjects; M = mean β2-microglobulin concentration (mg/L) 
 
 
Table 5. β2-microglobulin concentration in three control age groups. 
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Hip joint sheath thickness was compared between patient and control group and tested for 
statistically significant between-group difference by use of t-test for independent samples, 
which yielded the following result: t=1.982; df=91; P>0.05. There was no statistically 
significant difference in hip joint sheath thickness between control group and patient group 
on hemodialysis for <36 months. However, comparison of hip joint sheath thickness 
between control group and patient groups on hemodialysis for 36-72 and >72 months 
yielded a statistically significant difference bilaterally, i.e. thickness of the hip joint sheath 
was statistically significantly greater in both patient groups. Thickness of articular effusion 
in the hip region was also compared between control group and patient groups with 
different length of hemodialysis. Intra-articular effusion was statistically significantly 
greater bilaterally in all three patient groups having undergone hemodialysis for <36, 36-72 
and >72 months as compared to control subjects. The length of hemodialysis influenced the 
rate of hip joint intra-articular effusion. Thickness of the hip joint intra-articular effusion 
according to patient age and length of hemodialysis is shown in Table 6 A and B. 
 
 
 
 
Age 
(yrs) 
Length of hemodialysis 
<36 months 36-72 months >72 months 
n M Min Max n M Min Max n M Min Max 
18-50 8 5.26 3.50 6.90 5 6.02 2.90 9.70 3 6.30 5.10 8.60 
51-65 10 5.41 3.20 7.70 9 5.87 3.30 8.90 7 6.40 4.20 8.30 
>65 24 6.14 3.90 11.5 23 6.86 4.40 9.40 17 7.06 2.70 11.0 
Total 42 5.80 3.20 11.5 37 6.50 2.90 9.70 27 6.80 2.70 11.0 
n = number of subjects; M = mean (mm) 
 
Table 6A. Number of subjects and hip joint intra-articular effusion according to age and 
length of hemodialysis.    
 
 
 
 
Age (yrs) 
Length of hemodialysis 
Total 
n M Min Max 
18-50 16 5.69 2.90 9.70 
51-65 26 5.84 3.20 8.90 
>65 64 6.64 2.70 11.5 
Total 106 6.30 2.70 11.5 
n = number of subjects; M = mean (mm) 
 
Table 6B. Number of subjects and hip joint intra-articular thickness according to age and 
length of hemodialysis (total). 
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5. Discussion 
Complications involving the osteoarticular system are common in CRF patients. These 
complications develop at a slow rate, their clinical signs make only the tip of the iceberg that 
mostly indicate an advanced stage of the disease and are generally due to renal 
osteodystrophy and hemodialysis-related amyloidosis. Increased intra-articular effusion 
and greater hip joint sheath thickness are not specific changes and may occur 
consequentially to many other pathologic conditions. There are numerous diagnostic 
procedures to detect and follow-up changes in the osteoarticular system. As most of these 
methods are associated with high requirements related to duration, price, equipment, room, 
exposure to ionizing radiation, invasiveness and potential complications, ultrasonography 
imposes itself as an inexpensive, noninvasive, presumptive, widely available and repeatable 
examination free from ionizing radiation. As dialysis-related amyloidosis is a multifactorial 
disease and its pathogenesis has not yet been fully clarified, we embarked upon this study 
to assess the effect of patient age, hemodialysis duration and β2-microglobulin 
concentration on morphological changes in the hip region. Thickness of the hip joint sheath 
and magnitude of intra-articular effusion were found to be proportional to the length of 
hemodialysis. Thus, early lesions of the osteoarticular system can be detected by measuring 
the magnitude of articular effusion in the hip area. The increase in intra-articular effusion 
could be explained by changes involving joint sheath and cartilage due to hemodialysis-
related amyloidosis and initial signs of chronic arthropathy in patients with dialysis-related 
amyloidosis. Biochemical and histologic tests of joint structures can explain the presence of 
articular effusion and lesions involving the osteoarticular system. In CRF patients, the level 
of advanced glycation endproducts (AGE) is considerably elevated. These endproducts are 
formed in the state of uremia via nonenzymatic pathway, primarily by oxidative reactions as 
part of chronic inflammation in CRF patients (Miyata et al., 1999; Sugiyama et al., 1998; 
Wada et al., 1999;). Elevated AGE levels are found in all tissues, in particular collagenous 
amyloid structures, which is produced at an increased rate due to impaired metabolism and 
higher production of β2-microglobulin as a major amyloid component. AGEs are deposited 
in collagen to cause its structural changes and making it liable to mechanical changes 
(Miyata et al., 1994). The amount of articular effusion can be influenced by AGEs, which 
attract monocytes via chemotaxis, stimulating them for synthesis of the tumor necrosis 
factor-α (TNF-α) and interleukin-1β (IL-1β) cytokines. The synovial sheath intima contains 
macrophages, while fibroblasts account for 70% of intimal cells. Cytokines stimulate 
synovial fibroblasts for collagenase synthesis. Thus, synovial fibroblasts may be involved in 
the cellular inflammatory reaction associated with joint damage and destruction in 
hemodialysis-related amyloidosis (Koski et al., 1989). Protein matrix is degraded by 
collagenase. Degraded collagen attracts monocytes via chemotaxis, stimulating them for 
further TNF-α and IL-1β synthesis, thus creating a vicious circle (Miyata et al., 1994; Koski et 
al., 1989). Cytokines act upon the joint cartilage collagen and irritate synovial sheath of the 
joint, resulting in greater amount of intra-articular fluid. These biochemical reactions are 
supported by histologic studies demonstrating the initial occurrence of amyloid deposits on 
the joint cartilage. Burgeson and Nimmi (1992) found these amyloid deposits to be initially 
accumulated in the cartilage predominated by type I collagen. Jadoul et al. (1997) used 
histology to detect initial accumulation of paucicellular amyloid deposits surrounded by 
macrophages on joint cartilage, supporting the inflammatory nature of amyloid deposits. 
Zhang et al. (2002) report on β2-microglobulin inhibitory action on joint cartilage 
www.intechopen.com
 
Hemodialysis - Different Aspects 
 
132 
chondrocytes. Subsequent changes involve synovium, joint sheaths and tendons. Menerey et 
al. (1988) demonstrated the presence of amyloid in synovial fluid. These alterations may 
mark the onset of degenerative changes, erosions and effusions in the joints. Jadoul et al. 
(1993) found thickness of the hip joint sheath and supraspinous muscle tendon to correlate 
with the length of hemodialysis in 49 patients undergoing hemodialysis for a mean of 97 
months. After 21 months of hemodialysis, measurement  was repeated in 16 patients to 
show a statistically significant increase in the hip joint sheath thickness in nine patients 
(from 7.0±0.8 mm to 8.2±2.3 mm). On repeat measurement, there was no statistically 
significant increase in thickness of the supraspinous muscle tendon (from 6.6±0.4 mm to 
7.0±0.8 mm). Jeloka et al. (2001) compared hip joint sheath thickness between 30 patients 
undergoing hemodialysis for a mean of 7.1 years and 20 control subjects. The mean hip joint 
sheath thickness was 8.19 mm and 5.06 mm, and mean serum β2-microglobulin 
concentration 25.6±4.12 mg/L and 2.6±1.73 mg/L in patients and control subjects, 
respectively. In hemodialysis patients, serum β2-microglobulin concentration was 
statistically significantly lower while on hemodialysis with low-flux hemodialyzers as 
compared with the time on hemodialysis with high-flux hemodialyzers. The authors 
demonstrated correlation between the hip joint sheath thickness and the length of 
hemodialysis. The longer the time of hemodialysis, the greater was the hip joint sheath 
thickness. The authors conclude that osteoarticular system changes in hemodialysis patients 
can be followed-up by measurement of the hip joint sheath thickness. Most authors agree 
that changes in the osteoarticular system are related to the length of hemodialysis (Jadoul et 
al., 1993; Jeloka et al., 2001). In the present study, we found no statistically significant 
difference in β2-microglobulin concentration among the three patient age groups, nor 
recorded any effect of age on morphological changes in the hip area. There are literature 
reports on the carpal tunnel syndrome, amyloid arthropathy and amyloid bone cysts to be 
more common in elderly patients (Denesh & Ho, 2001; Shin et al., 2008).  
The mechanism by which patient age influences the prevalence of complications in 
hemodialysis patients remains unknown. The concentration of AGEs is higher in elderly 
subjects (Sell & Monnier, 1990). As AGEs influence collagen metabolism, it may explain 
the impact of age on anatomic structure changes in this population. Schiffl et al. (2000) 
investigated the prevalence of complications involving osteoarticular system in 
hemodialysis patients aged <55 and >55. The latter had a higher rate of complications 
including carpal tunnel syndrome, amyloid arthropathy and bone cysts as compared to 
patients aged <55 at the time of starting hemodialysis. The older patient age, the higher 
was the rate of complications. The time elapsed from starting hemodialysis to the onset of 
complications was shorter in older than in younger patients. Kurer et al. (1991) found 
carpal tunnel syndrome to be more common in elderly patients and in those starting 
hemodialysis at an older age. In older patients, carpal tunnel syndrome developed after a 
shorter period of hemodialysis than in younger ones. However, opposite results have also 
been reported in the literature. Using the Glasgow Ultrasound Enthesitis Scoring System 
(GUESS) scale, Kerimoglu et al. (2007) found changes of the osteoarticular system 
anatomic structures in hemodialysis patients to be related to the length of hemodialysis, 
while demonstrating no effect of patient age and β2-microglobulin concentration. 
Weybright et al. (2003) point to the possible misinterpretations and false-positive results 
of US measurement of articular effusion in the hip area. Ultrasonography performance is 
limited in overweight patients. Synovial membrane of the hip joint covers fibrous 
membrane and cannot be visualized on US. Hypoechogenic synovia may push as the 
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articular sheath, thus yielding an image of articular effusion. This is especially 
pronounced in obese subjects, where hypoechogenic synovia may appear as articular 
effusion on US. In our study, β2-microglobulin concentration influenced the hip joint 
sheath thickness in the group of patients on hemodialysis for <36 months, whereas no 
statistically significant correlation was observed in the other two patient groups. Serum 
β2-microglobulin concentration had no effect on the amount of articular effusion in the 
hip area in any patient group with different length of hemodialysis. In addition, there was 
no statistically significant difference in β2-microglobulin concentration among the three 
patient groups, however, β2-microglobulin concentration was higher in patients with 
longer hemodialysis duration. A high serum β2-microglobulin concentration is one of the 
preconditions for the development of hemodialysis-related amyloidosis; therefore, higher 
β2-microglobulin concentration is expected to be associated with more pronounced 
morphological changes of anatomic structures. There are no reports on hemodialysis-
related amyloidosis in patients with β2-microglobulin concentration <10 mg/L (Farrell & 
Bastani, 1997). Because of different dialyzer membrane properties, β2-microglobulin 
concentration is by 30% lower in patients on hemodialysis with low-flux hemodialyzers 
(Jadoul, 1998). In their study including 50 patients, McCarthy et al. (1997) found residual 
kidney function to be preserved for a longer time in patients on hemodialysis with high-
flux hemodialyzers. During the first 12-24 months of hemodialysis, β2-microglobulin 
concentration also depends on residual kidney function, i.e. the longer it is preserved, the 
later the onset of amyloidosis complications (Schiffl et al., 2000). The membrane of high-
flux hemodialyzers is characterized by higher biocompatibility and lower rate of 
stimulating β2-microglobulin concentration production through complement activation. 
The high-flux dialyzer membrane can remove β2-microglobulin molecules and AGE 
modified proteins, thus influencing the process of amyloid formation (Henle et al., 1999; 
Jadoul, 1998). Therefore, the use of high-flux dialyzers is expected to be associated with a 
lower rate of complications involving the osteoarticular system (Geyo, 2001). Beta2-
microglobulin concentration does not correlate with the activity of dialysis-related 
amyloidosis, thus serum β2-microglobulin concentration is not a diagnostic test to 
determine the severity of dialysis-related amyloidosis (Farrell & Bastani, 1997; Koski et al., 
1989). A number of studies have confirmed that clinical symptoms of complications 
involving the osteoarticular system are more common in patients undergoing 
hemodialysis for a prolonged period of time, as well as in those with higher  β2-
microglobulin concentration (Barišić et al., 2007). 
Shin et al. (2008) compared two groups of patients with different β2-microglobulin 
concentration and found the prevalence of carpal tunnel syndrome to be lower in patients 
with lower β2-microglobulin concentration. Barišić et al. (2007) report on a higher β2-
microglobulin concentration in the group of hemodialysis patients articular pain as 
compared with those free from articular pain. In contrast, Kerimoglu et al. (2007) found no 
statistically significant correlation between GUESS scale and serum β2-microglobulin 
concentration. In the present study, intra-articular effusion in the hip area was statistically 
significantly greater bilaterally in all three hemodialysis patient groups as compared with 
control group. Difference in the hip joint sheath thickness did not reach statistical 
significance between control group and the group of patients on hemodialysis for <36 
months, but was statistically significant in the groups of patients on hemodialysis for 36-72 
and >72 months. 
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6. Conclusion 
The present study demonstrated that changes involving osteoarticular system soft tissues in 
CRF patients could be followed-up by use of US. Although the National Kidney Foundation 
Kidney Disease Outcomes Quality Initiative (NKF KDOQI, 2003) recommendations do not 
recommend routine follow up of CRF patients by β2-microglobulin amyloidosis because 
there is no therapeutic option other than kidney transplantation for hemodialysis-related 
amyloidosis, we consider US a useful and widely available diagnostic method to detect and 
follow-up soft tissue changes in hemodialysis patients. In our study, pre-hemodialysis 
serum β2-microglobulin concentration did not influence the magnitude of articular effusion, 
but did influence hip joint sheath thickness in patients undergoing hemodialysis for <36 
months, with no statistically significant correlation recorded in the other two groups of 
patients. Morphological changes correlated with the length of hemodialysis, but not with 
patient age. As the osteoarticular system changes are multifactorial, additional studies are 
needed to determine the effect of particular factors on these changes in CRF patients. 
Research should be focused on complications in patients undergoing hemodialysis with 
high-flux dialyzers in order to identify the possible impact of the type of hemodialyzers on 
osteoarticular system changes. US study is the method of choice to follow-up the dynamics 
of changes involving soft tissue structures (Bother et al., 2006; Drüeke, 1999; Kay et al., 1962; 
Kerimoglu et al., 2007; Kiss et al., 2005; Negi et al., 1995). Early and asymptomatic lesions of 
the joints, tendons and ligaments can be detected by US (Barišić et al., 2002; Jeloka et al., 
2001; Lanteri et al., 2000; Takahashi et al., 2002). The need for the best possible care of 
hemodialysis patients points to the use of US as a adjunctive method to clinical examination 
to assess soft tissue changes of the osteoarticular system by providing better insight into the 
pathology of articular tendons, ligaments, cartilage and effusion (Backhaus et al., 2001; 
Takahashi et al., 2002). US analysis of morphological changes of the osteoarticular system 
can be of prognostic value in patients undergoing hemodialysis. Maintaining good function 
of the osteoarticular system helps the CRF patients achieve appropriate social inclusion and 
better quality of life, while reducing the cost of treatment for severe complications. 
7. Acknowledgments 
The authors would like to ancnowledge the LIMA – O.I. d.o.o. Zagreb for their financial 
support for this project. 
8. References 
Al-Taee IK, Al-Safar JJ, Al-Falahi YS, Al-Shamma IA. The Clinical Significance of β2-
microglobulin un End-Stage Renal Disease. Saudi J Kidney Dis Transpl 
2003;14(4):492-6. 
Backhaus M, Burmester GR, Gerber T, Grassi W, Machold KP, Swen WA, i sur. Gudelines 
for muscolosceletal ultrasound in reumatology. Ann Rheum Dis 2001;60(7): 
641-9. 
Barišić I, Ljutić D, Vlak T, Bekavac J, Janković S. Laboratory and sonographic findings in 
dialyzed patients with bilateral chronic knee pain versus dialyzed asymptomatic 
patients. Coll Antropol 2007;31(2):489-94. 
www.intechopen.com
The Role of Ultrasonographic Monitoring  
for Hip Joint Changes in Patients with Chronic Renal Failure 
 
135 
Barišić I, Wilhelm V, Štambuk N, Karaman K. Janković S, Konjevoda P, i sur. Machine 
Learning Based Analysis of Biochemical and Morphological Parameters in Patients 
with Dialysis Releated Amyloidosis. Croat Chem Acta 2002;75(4):935- 
44. 
Bother LA, Barbosa ABR, Sicca JA, Oliviera GR, Silva MRC, Germano M, i sur. 
Ultrasonography evaluation of tendon thickness in haemodialysis patients. Einstein 
2006;4(4):303-8. 
Burgeson  RE, Nimmi ME. Collagen types. Molecular structure and tissue distribution. Clin 
Orthop Relat Res 1992;282:250-72.  
Connors LH, Shirahama T, Sipe JD, Skinner M, Fenves A,Cohen AS: Formation of amyloid 
fibrils from intact β2-microglobulin. Biochem Biophys Res Commun 1985;131:1063-
8. 
Denesh F, Ho LT.  Dyalisis-releated amyloidosis: history and clinical manifestations. Semin 
Dial 2001;14(2):80-5. 
Drüeke TB. Ekstraskeletal problems and amyloid. Kidney Int Suppl 1999;73:S89-93. 
Farrell J, Bastani B. Beta 2-microglobulin amyloidosis in chronic dialysis patients: a case 
report and review of the literature. J Am Soc Nephrol 1997;8:509-14. 
Fitzpatrick DC, Jebson PJL, Madey SM, Steyers CM. Upper extremity musculosceletal 
manifestations of dialysis-associated amyloidosis. Iowa Orthop J 1996;16:135- 
38. 
Floege J, Schäffer J, Koch KM. Scintigraphic methods to detect beta2-microglobulin 
associated amyloidosis (Abeta2-microglobulin amyloidosis). Nephrol Dial 
Transplant 2001;16 Supp l4:12-6. 
Fukuda K, Yamamoto H. Dialysis-releated amyloidosis. Semin Musculoscelet Radiol 
2001;5(2):113-9. 
Geyo F. Beta 2-microglobulin and dialysis-releated amyloidosis. Rinsho Byori 
2001;49(3):244-8.  
Geyo F, Yamada T, Odani S, Nakagawa Y, Arakawa M, Kunimoto T, i sur. A new form of 
amyloid protein associated with chronic hemodialysis was identified as beta 2-
microglobulin. Biochem Biophys Res Commun 1985;129:701-6. 
Hawkins PN, Lavender JP, Pepys MB.Evaluation of systemic amyloidosis by scintigraphy 
with 123I-labeled serum amyloid P component. N Engl J Med 1990 Aug 
23;323(8):542-3.  
Henle T, Deppisch R, Beck W, Hergesell O, Hänsch GM, Ritz E. Advanced glycated end-
products (AGE) during haemodialysis treatment: discrepant results with different 
methodologies reflecting the heterogeneity of AGE compounds. Nephrol Dial 
Transplant 1999;14(8):1968-75.  
Ikegava N, Hishida A, Sawada K, Furuhashi M, Maruyama Y, Kumagai H, i sur. 
Ultrasonographic evaluation of the carpal tunnel syndrome in hemodialysis 
patients. Clin Nephrol 1995;44(4):231-7. 
Jadoul M. Dialysis-releated amyloidosis:importance of biocompatibility and age. Nephrol 
Dial Transplant 1998;13 Suppl 7:61-4. 
www.intechopen.com
 
Hemodialysis - Different Aspects 
 
136 
Jadoul M, Garbar C, Noel H, Sennesael J, Vanholder R, Bernaert P. et al. Histological 
prevalence of beta2-microglobulin amyloidosis in haemodialysis: A prospective 
post-mortem study. Kidney Int 1997;92:1928-52. 
Jadoul M, Malghem J, vande Berg, B, van Ypersele de Strihou C. Ultrasonographic detection 
of thickened joint capsules and tendons as marker of dialysis-releated amyloidosis: 
a cross-sectional and longitudinal study. Nephrol Dial Transplant 1993;8(10): 
1104-9. 
Jeloka T, Mathur MD, Kaur R, Kohli R, Singh NP, Rizvi SNA.  β2 Microglobulin in chronic 
renal failure and effect of different dialyser membrane on its clearance. Indian J 
Nephrol 2001;11:160-4.  
Jimenez RE, Price DA, Pinkus GS, Owen WF Jr, Lazarus JM, Kay J, i sur. Development of 
gastrointestinal beta2-microglobulin amyloidosis correlates with time on dialysis. 
Am J Surg Pathol 1998;22(6):729-35. 
Kay J, Benson CB, Lester S, Corson JM, Pinkus GS, Lazarus JM, i sur. Utility of high-
resolution ultrasound for the diagnosis of dialysis-related amyloidosis. Arthritis 
Rheum 1992;35(8): 926-32. 
Kelly A, Apostle K, Sanders D, Bailey H. Musculosceletal pain in dialysis-releated 
amyloidosis. Can J Surg 2007;50(4)305-6. 
Kenzora JE. Dialysis carpal tunnel syndrome. Orthopaedics 1978;1:195-203. 
Kerimoglu U, Hayran M, Ergen FB, Kirpanktur A, Turgan C. Sonographic evaluation of 
entheseal sites of the lower extremity in patients undergoing hemodialysis. J Clin 
Ultrasound 2007;35(8):417–23. 
Ketteler M, Koch KM, Floege J. Imaging techniques in the diagnosis of dialysis-releated 
amyloidosis. Semin Dial 2001;14(2):90-3. 
Kiss E, Keusch G, Zanetti M, Jung T, Schwarz A, Schocke M, i sur. Dialysis-releated 
amyloidosis revisited. AJR Am J Roentgenol 2005;185(6)1460-7. 
Koski JM, Anthila PJ, Isomaki HA. Ultrasonography of the adult hip joint. Scand J 
Rheumatol 1989;18:113-7. 
Kurer MH, Baillod RA, Madqwick JC. Musculosceletal maifestations of amyloidosis. A 
reiew of 83 patients on haemodyalysis for at least 10 years. J. Bone Joint Surg Br 
1991;73(2):271-6. 
Lanteri M, Ptasznik R, Hennesy O, Constable L, Dawborn JK. Ultrasound assesment of large 
joint amyloidosis in haemodialysis. Nephrology 2000;5:45-50. 
Linke RP, Schäeffer J, Gielow P, Lindner P, Lottspeich F, Plückthun A, i sur. Production of 
recombinant humen beta2-microglobulin for scintigraphic diagnosis of amyloidosis 
in uremia and hemodialysis. Eur J Biochem 2000;267(3):627-33. 
McCarthly JT, Jenson BM, Squillace DP, Williams AW. Improved preservation of residual 
function in chronic hemodialysis patients using polysulfone dialyzers. Am I Kidney 
Dis 1997;29:576-83.  
Menerey K, Braunstein E, Brown M, Swartz R, Brown C, Fox IH. Musculosceletal  symptoms 
related to arthropathy in patients receiving dialysis. J Rheumatol 1988; 15:1848-54. 
Miyata T, Inagi R, Kurokawa K. Diagnosis, pathogenesis, and treatment of dialysis-related 
amyloidosis. Miner Electrolyte Metab 1999;25(1-2):114-7. 
www.intechopen.com
The Role of Ultrasonographic Monitoring  
for Hip Joint Changes in Patients with Chronic Renal Failure 
 
137 
Miyata T, Inagai R, Lida Y, Sato M, Yamada N, Oda O, Maeda K, Seo H. Involvement β2-
microglobulin modified with advanced glycation end product in the pathogenesis 
of haemodialysis-associated amyloidosis. Induction of human monocyte 
chemotaxis and macrophage secretion of THF and IL-1. J Clin Invest 1994;93: 
521-9. 
Motomiya Y, Ando Y, Haraoka K, Sun X, Iwamoto H, Uchimura T, i sur. Circulating level of 
alfa2-microglobulin-beta2-microglobulin complex in hemodialysis patients. Kidney 
Int 2003;64(6):2244-52. 
National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and 
disease in chronic kidney disease. Am J Kidney Dis 2003:42(Suppl3):S1-201.3 
Negi S, Kita Y, Uchita K, Abe T. Ultrasonographic evaluation of shoulder joints in 
hemodialysis patients. Nippon Jinzo Gakkai Shi 1995;37(1):29-34. 
Ohashi K. Pathogenesis of beta-2-microglobulin amyloidosis. Pathol Int 2001;51(1):1- 
10. 
Schiffl H, Fischer R, Lang SM, Mangel E. Clinical manifestations of AB-amyloidosis: effects 
of biocompatibility. Nephrol Dial Transplant 2000;15:840-5. 
Shin J, Nishioka M, Shinko S, Shibuya K, Sugiki M, Kasumoto H, i sur. Carpal tunnel 
syndrome and plasma beta2-microglobulin contcentration in hemodialysis patients. 
Ther Apher Dial 2008;12(1):62-6. 
Sell DR, Monnier VM. End-stage renal disease and diabetes catalyze the formation of a 
pentose-derived crosslink from aging human collagen. J Clin Invest 1990;85(2):380–
4. 
Sugiyama S, Miyata T, Inagi R, Kurokawa K. Implication of the glycoxidation and 
lipoxidation reactions in the pathogenesis of dialysis-related amyloidosis (Review). 
Int J Mol Med 1998;2(5):561-5. 
Takahashi T, Kato A, Ikegaya N, Takita T, Maruyama Y, Hishida A, i sur. Ultrasound 
changes of the carpal tunnel in patients receiving long-term hemodialysis: a cross-
sectional and longitudinal study. Clin Nephrol 2002;57(3):230-6. 
Tsvetkova S, Blagov B, Batalov A. Amyloid arthropathy in haemodialysis patients-
radiological findings. Journal of IMAB-annual proceeding. (scientific papers) 2007; 
book 2: 46-48. 
Zhang H, Liew CC, Marshall KW. Microarray analysis reveals the involvement of beta-2-
microglobulin (B2M) in human osteoarthritis. Osteoarthritis Cartilage 
2002;10(12):950-60. 
Wada T, Miyata T, Sakai H, Kurokawa K. Beta2-microglobulin and renal bone disease. Perit 
Dial Int 1999;19 Suppl 2:S413-6. 
Warren DJ, Otieno LS. Carpal tunnel syndrome in patients on intermittent hemodialysis. 
Postgrad Med J 1975;51:450-2. 
Weybright PN, Jacobson JA, Murry KH, Lin J, Fessell DP, Jamadar DA, i sur.  Limited 
effectivness of sonography in revealing hip joint effusion: preliminary results in 21 
adult patients with native and postoperative hips. AJR Am J Roentgenol 
2003;181(1):215-8. 
www.intechopen.com
 
Hemodialysis - Different Aspects 
 
138 
Yamamoto S, Kazama JJ, Maruyama H, Nishi S, Narita I, Geyo F. Patients undergoing 
dialysis therapy for 30 years or more survive with serious osteoarticular disorders. 
Clin Nephrol 2008;70(6):496-502. 
www.intechopen.com
Hemodialysis - Different Aspects
Edited by Prof. Maria Goretti Penido
ISBN 978-953-307-315-6
Hard cover, 321 pages
Publisher InTech
Published online 14, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The book provides practical and accessible information on all aspects of hemodialysis, with emphasis on day-
to-day management of patients. It is quite comprehensive as it covers almost all the aspects of hemodialysis.
In short it is a valuable book and an essential aid in the dialysis room.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Damir Matokovic ́, Miroslav Has ̌pl, Petar Petric ́, Sanja Škorvaga, Vlado Drkulec and Goran Šantak (2011). The
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